A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)

Inclusion Criteria: * Male or female, \>/= 6 months * Ability to take oral medication * Acute uncomplicated P. falciparum monoinfection * Asexual P. falciparum parasitaemia: 96 to 200,000/µL, determined on a peripheral blood film * Fever defined as \>/= 37.5°C tympanic temperature or a history of fever within the last 24 hours * Written informed consent by the subject or parent/guardian in case of children lower than the age of consent and assent if required (per local regulations) * Willingness and ability of the subjects or parents/guardians to comply with the study protocol for the duration of the study Exclusion Criteria: * Signs of severe malaria (adapted from WHO criteria) * Patients not fulfilling criteria for severe malaria but with another indication for parenteral antimalarial treatment at the discretion of the treating physician * Haematocrit \< 20% at screening * Subjects who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine within the previous 30 days * Acute illness other than malaria requiring systemic treatment * Severe acute malnutrition * Known HIV infection * Known tuberculosis infection * For females: pregnant, trying to get pregnant or are lactating * History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy * Previous splenectomy * Enrolment in DeTACT in the previous 3 months * Parti…